Reyataz

Reyataz

atazanavir

Manufacturer:

Bristol-Myers Squibb

Distributor:

DKSH
Concise Prescribing Info
Contents
Atazanavir sulfate
Indications/Uses
HIV-1 infection in combination w/ other antiretroviral agents.
Dosage/Direction for Use
Treatment-naive patient 400 mg; or Reyataz 300 mg + ritonavir 100 mg. Treatment-experienced patient Reyataz 300 mg + ritonavir 100 mg. All doses to be taken once daily. Concomitant therapy: Reyataz 300 mg + ritonavir 100 mg + tenofovir 300 mg. Paed & adolescent (6 to <18 yr) ≥40 kg body wt Reyataz 300 mg + ritonavir 100 mg, 20 to <40 kg body wt Reyataz 200 mg + ritonavir 100 mg, 15 to <20 kg body wt Reyataz 150 mg + ritonavir 100 mg. All as single daily dose.
Administration
Should be taken with food.
Contraindications
Hypersensitivity. Concomitant drugs that are highly dependent on CYP3A4 for clearance.
Special Precautions
Not for treatment-experienced patient w/ prior virologic failure or severe renal impairment managed w/ hemodialysis. Mild to moderate hepatic impairment. New-onset DM, exacerbation of preexisting DM, hyperglycemia, hemophilia, fat redistribution, immune reconstitution syndrome. Preexisting conduction system disease or co-administration w/ drugs that induce PR interval prolongation. Discontinue in case of severe rash or nephrolithiasis. Childn <3 mth. Pregnancy (2nd or 3rd trimester) & lactation.
Adverse Reactions
Jaundice, headache, scleral icterus, abdominal pain, diarrhoea, dyspepsia, nausea, vomiting, rash, asthenia, fatigue.
Drug Interactions
Rifampin, irinotecan, lovastatin, simvastatin, salmeterol, indinavir, Ca channel blockers, HMG-CoA reductase inhibitors, immunosuppressants, phosphodiesterase (PDE5) inhibitors, didanosine, tenofovir, efavirenz, nevirapine, protease inhibitors, antacids & buffered medications, amiodarone, lidocaine (systemic), quinidine, warfarin, TCAs, trazodone, ketoconazole, itraconazole, voriconazole, colchicine, rifabutin, bosentan, proton-pump inhibitors, H2-receptor antagonists, inhaled/nasal corticosteroids, clarithromycin, midazolam, parenteral triazolam, buprenorphine, OC.
MIMS Class
ATC Classification
J05AE08 - atazanavir ; Belongs to the class of protease inhibitors. Used in the systemic treatment of viral infections.
Presentation/Packing
Form
Reyataz cap 300 mg
Packing/Price
30's
Form
Reyataz cap 200 mg
Packing/Price
60's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in